OTCMKTS:GMXAY

GENMAB A/S/S (GMXAY) Stock Price, News & Analysis

GENMAB A/S/S logo
$50.60 -0.75 (-1.46%)
As of 11/20/2026

About GENMAB A/S/S Stock (OTCMKTS:GMXAY)

Advanced

Key Stats

Today's Range
$50.24
▼
$51.72
50-Day Range
$32.47
▼
$57.06
52-Week Range
$12.10
▼
$19.00
Volume
2.90 million shs
Average Volume
48,553 shs
Market Capitalization
N/A
P/E Ratio
19.42
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1999, it discovers and develops antibody-based medicines for the treatment of cancer and other serious diseases. Its research uses proprietary antibody technologies, including platforms designed to create multispecific antibodies and antibody-drug conjugates.

Genmab’s products and development programs include treatments developed independently and with pharmaceutical partners. Its collaborations have helped bring medicines such as Darzalex (daratumumab), Epkinly/Tepkinly (epcoritamab) and Tivdak (tisotumab vedotin) to market. The company also advances a pipeline of investigational antibody therapies.

Genmab works with partners to develop and commercialize medicines internationally, serving patients across multiple regions. Co-founder Jan van de Winkel has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Receive GMXAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GMXAY Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
Genmab A/S ADR
A Peek at Genmab's Future Earnings
Genmab: Darzalex Growth Fuels Rally, Upside Is Tight
See More Headlines

GMXAY Stock Analysis - Frequently Asked Questions

GENMAB A/S/S's stock was trading at $33.42 at the beginning of 2026. Since then, GMXAY stock has increased by 51.4% and is now trading at $50.60.

Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:GMXAY
CIK
N/A
Fax
N/A
Employees
1,660
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
19.42
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:GMXAY) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners